FDA Grants Priority Review for Gilead's Once-Daily HIV Treatment, PDUFA Set for August
Summary
The U.S. FDA has granted Priority Review to Gilead Sciences' New Drug Application (NDA) for its once-daily HIV treatment, a combination of bictegravir and lenacapavir. This designation accelerates the review timeline, indicating the FDA believes the drug could offer significant improvements over existing therapies. For Gilead, a leader in HIV therapeutics, this is a positive development that could expedite the launch of a new product in a core franchise, potentially strengthening its market position and future revenue streams. The Prescription Drug User Fee Act (PDUFA) date is set for August 27, 2026, marking the next key catalyst for investors to monitor.
At the time of this announcement, GILD was trading at $128.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.8B. The 52-week trading range was $95.30 to $157.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.